TAK-875

TAK-875 is a selective GPR40 agonist with EC50 of 14 nM, 400-fold more potent than oleic acid.

Price Stock Quantity  
In DMSO USD 580 In stock
USD 270 In stock
USD 370 In stock
USD 970 In stock
USD 2670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

TAK-875 Chemical Structure

TAK-875 Chemical Structure
Molecular Weight: 533.63

Validation & Quality Control

Customer Reviews(1)

Quality Control & MSDS

Related Compound Libraries

TAK-875 is available in the following compound libraries:

Product Information

  • Compare GPR Modulators
    Compare GPR Products

Product Description

Biological Activity

Description TAK-875 is a selective GPR40 agonist with EC50 of 14 nM, 400-fold more potent than oleic acid.
Targets GPR40
IC50 14 nM [1](EC50)
In vitro TAK-875 exhibits potent agonist activity and high binding affinity to the human GPR40 receptor with Ki of 38 nM. TAK-875 displays weaker affinity toward the rat GPR40 receptor with Ki of 140 nM. TAK-875 displays excellent selectivity, as TAK-875 has little agonist potency to other members of the FFA receptor family with EC50 of >10 μM. [1] TAK-875 treatment induces a concentration-dependent increase in intracellular IP production in CHO-hGPR40 with EC50 of 72 nM, more potently than that of endogenous ligand agonist oleic acid which requires much higher ligand concentrations to activate the receptor with EC50 of 29.9 μM. Neither TAK-875 nor oleic acid elicits an IP response in control CHO cells devoid of hGPR40. Consistent with the activation of the Gqα-mediated signaling pathway, TAK-875 augments glucose-dependent insulin secretion in pancreatic β cells. Prolonged stimulation of GPR40/FFA1 by TAK-875 does not cause pancreatic β Cell dysfunction or induction of apoptosis. [2]
In vivo In a rat model of diabetes, single oral dosing of TAK-875 at 0.3-3 mg/kg reduces the blood glucose excursion and augments insulin secretion during an oral glucose tolerance test, when TAK-875 is administered 1 hour before an oral glucose challenge. [1] In type 2 diabetic N-STZ-1.5 rats, administration of TAK-875 (1-10 mg/kg p.o.) shows a clear improvement in glucose tolerance and augments insulin secretion. Additionally, TAK-875 (10 mg/kg, p.o.) significantly augments plasma insulin levels and reduces fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhances insulin secretion nor causes hypoglycemia even at 30 mg/kg. [2]
Features More potent at activating hGPR40 than oleic acid.

Protocol(Only for Reference)

Kinase Assay: [1]

Ca influx activity of CHO cells expressing human GPR40 (FLIPR assay) CHO cells stably expressing human GPR40 are plated and incubated overnight in 5% CO2 at 37 °C. Then, cells are incubated in loading buffer (recording medium containing 2.5 μg/mL fluorescent calcium indicator Fluo 4-AM, 2.5 mM probenecid and 0.1% fatty acid-free BSA) for 60 minutes at 37 ºC. Various concentrations of TAK-875 are added into the cells and increase of the intracellular Ca2+ concentration after addition is monitored by FLIPR Tsystem for 90 seconds. EC50 value of TAK-875 is obtained with Prism 5 software.

Animal Study: [1]

Animal Models Female Wistar fatty rats subjected to oral glucose tolerance test
Formulation Formulated in 0.5% methylcellulose
Dosages ~3 mg/kg
Administration Orally
Solubility 0.5% CMC/0.25% Tween 80, , 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
1

References

[1] Nobuyuki Negoro, et al. ACS Med Chem Lett, 2010, 1(6), 290-294.

[2] Tsujihata Y, et al. J Pharmacol Exp Ther, 2011, 339(1), 228-237.

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01829464 Terminated Diabetes Takeda 2013-05 Phase 3
NCT01834274 Terminated Diabetes Mellitus, Type 2 Takeda 2013-06 Phase 3
NCT01829477 Terminated Diabetes Mellitus, Type 2 Takeda 2013-07 Phase 3
NCT01982253 Terminated Type 2 Diabetes Mellitus Takeda 2013-11 Phase 2
NCT02015780 Withdrawn Type 2 Diabetes Mellitus|Chronic Kidney Disease Takeda 2013-12 Phase 3

Chemical Information

Download TAK-875 SDF
Molecular Weight (MW) 533.63
Formula

C29H32O7S.1/2H2O

CAS No. 1374598-80-7
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms
Solubility (25°C) * In vitro DMSO 100 mg/mL (187 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphe-nyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate

Research Area

Customer Reviews (1)


Click to enlarge
Rating
Source Journal of Surgical Research, 2014, doi:10.1016/j.jss.2014.01.037. TAK-875 purchased from Selleck
Method absorbance-based cell viability assay
Cell Lines Hs27, A2058, A375, SK-Mel 3, MCF-7
Concentrations 0-0.4 uM
Incubation Time 72 h
Results The selective GPR40 agonist, TAK- 875, also has a selective inhibitory effect on the growth of all three human melanoma cell lines tested without negatively effecting the growth of the control fibroblast or human breast cancer cell lines even at very high concentrations.

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related GPR Products

  • AZD1981

    AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1.

    Features:An orally available selective DP2(CRTh2) receptor antagonist in clinical development for asthma.

  • PD123319

    PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

  • AZD3514

    AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.

  • GSK1292263

    GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. Phase 2.

  • OC000459

    OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM.

  • GW9508

    GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.

    Features:The effects of GW9508 on insulin secretion are reversed by GW1100, while linoleic acid-stimulated insulin secretion is partially attenuated by GW1100.

  • Enzalutamide (MDV3100)

    Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

  • Fulvestrant

    Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM.

  • Tamoxifen Citrate

    Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.

  • Bicalutamide

    Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM.

Recently Viewed Items

Tags: buy TAK-875 | TAK-875 supplier | purchase TAK-875 | TAK-875 cost | TAK-875 manufacturer | order TAK-875 | TAK-875 distributor
Contact Us